Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00218218 · ClinicalTrials.gov registry record · Phase 2

Effects of Transdermal Nicotine on Smoking, Craving and Withdrawal in People With Schizophrenia

A Phase 2 study, sponsored by National Institute on Drug Abuse (NIDA).

Completed
Registry status
Phase 2
Development phase
48
Enrollment target

NCT00218218: Completed Phase 2 study, sponsored by National Institute on Drug Abuse (NIDA).

NCT00218218 is a Phase 2 study that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 48 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (64% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00218218, a Phase 2 study, has completed, sponsored by National Institute on Drug Abuse (NIDA).

COMPLETED
Registry status
Phase 2
Development phase
48 participants
Enrollment target

Study Summary

Individuals with schizophrenia are three times as likely to smoke cigarettes as individuals without schizophrenia. While a great deal of research has been focused on smoking cessation programs for healthy individuals, little attention has been directed towards developing an effective smoking cessation treatment for schizophrenics. This project will evaluate the effects of 0, 21 and 42 mg transdermal nicotine on smoking, urge to smoke, and nicotine withdrawal symptoms after 5 hrs abstinence in smokers with schizophrenia and heavy-smoking non-psychiatric control smokers.

Interventions

  • DRUG Transdermal Nicotine Patch
  • DRUG placebo patch
  • DRUG 21 mg transdermal nicotine

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2002-06
Est. Completion 2005-02
Phase Phase 2

What the finished NCT00218218 record still lists

NCT00218218 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (64% lower).

The record links to 0 conditions, and to 3 interventions - of which Transdermal Nicotine Patch is the first listed.

NCT00218218 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00218218 about?

NCT00218218 is a clinical study titled "Effects of Transdermal Nicotine on Smoking, Craving and Withdrawal in People With Schizophrenia". Individuals with schizophrenia are three times as likely to smoke cigarettes as individuals without schizophrenia. While a great deal of research has been focused on smoking cessation programs for healthy individuals, little attention has been directed towards developing an effective smoking cessati...

What is the current status of trial NCT00218218?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2002-06. Estimated completion is 2005-02.

What interventions are being tested in trial NCT00218218?

The interventions under investigation include: Transdermal Nicotine Patch (DRUG), placebo patch (DRUG), 21 mg transdermal nicotine (DRUG).

Who is sponsoring clinical trial NCT00218218?

This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00218218's enrollment target sits among peer trials

48 1265th of 2000 higher than 718 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01765777 · 48 participants · NA

    Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain

  • NCT03073343 · 48 participants · NA

    A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine

  • NCT03431064 · 48 participants

    Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients

  • NCT03514602 · 48 participants · NA

    Maternal Smoking Cessation and Pediatric Obesity Prevention

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00218218, the US trial registry maintained by the National Library of Medicine. NCT00218218 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.